Minerals Testing Leads ALS (ASX:ALQ) Growth as Pharma Revenue Softens

Sonal Goyal

22 October 2026 05:23 PM AEDT

Minerals Testing Leads ALS (ASX:ALQ) Growth as Pharma Revenue Softens

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

Als Ltd (ASX:ALQ) shares were up 0.79% at $20.31 during the trading session on 22 October 2026, while the S&P/ASX 200 Industrials [XNJ] index was up 1.05%.
ALS reported record low safety rates in FY26, with a TRIFR of 0.79 and an LTIFR of 0.29, according to its 28 July 2026 AGM address.
Minerals delivered 20.2% organic growth, Food 7.2% and Oil & Lubricants 12.2%, while Pharma revenue declined 1.6% organically.

Als Ltd (ASX:ALQ) was trading at $20.31 on 22 October 2026, up 0.79% during the session. The S&P/ASX 200 Industrials [XNJ] index was at 8,199.50, a rise of 1.05% (85.60 points), while the S&P/ASX 200 [XJO] was at 8,788.70, a rise of 0.48%, and the All Ordinaries was at 8,911.80, a rise of 0.50%, at 3:55 pm GMT+11. ALS is a global testing, inspection and certification company with operations in commodities, life sciences and other testing markets. ALS reported record low safety rates in FY26, with a TRIFR of 0.79 and an LTIFR of 0.29, according to its 28 July 2026 AGM address.

Share price snapshot

At $20.31, Als Ltd (ASX:ALQ) shares were up 0.79% during the trading session on 22 October 2026. Over the same session, the S&P/ASX 200 Industrials [XNJ] index was up 1.05% (85.60 points) at 8,199.50, the S&P/ASX 200 [XJO] was up 0.48% at 8,788.70 and the All Ordinaries was up 0.50% at 8,911.80, as at 3:55 pm GMT+11. The figures are intraday readings during the session and can change as trading continues. The company’s most recent announcement covered in this article is its AGM address.

About Als Ltd: business overview

ALS Limited provides laboratory testing and related services to customers in the commodities and life sciences sectors. Its Commodities business covers Minerals, Coal, Metallurgy, Industrial Materials and Oil & Lubricants, and its Life Sciences business covers Environmental, Food, Pharma and related testing. The company states that its Environmental business is its largest at about 35% of Group revenue.

FY26 performance in the AGM address

In an ASX release dated 28 July 2026, ALS published the address of its CEO and Managing Director to the 2026 Annual General Meeting, delivered remotely from Europe. The address describes FY26 as delivering record financial performance and returns, and sets out results by division.

In Commodities, Minerals delivered 20.2% organic growth in a record year, with margin expanding to 33%. Coal grew 7.6% organically and Oil & Lubricants 12.2%, though both saw margin contraction. In Life Sciences, Food delivered 7.2% organic growth for the third consecutive year, led by Europe. Pharma recorded a 1.6% organic revenue decline, while Nuvisan EBIT grew 123% with margin about 450 basis points higher after the successful completion of its transition.

Safety, strategy and technology

ALS reported a record low total recordable injury frequency rate of 0.79 and lost time injury frequency rate of 0.29. The address sets out the Roadmap to Win, a strategic blueprint that prioritises high-volume analytical testing and associated services in markets where ALS can build a competitive advantage. It also describes a Lab of the Future digital program: the unified LIMS supports 80% of Group revenue, and the company describes AI deployments across its operations.

Saudi joint venture and trading update

The CEO said ALS signed an agreement to acquire an additional 18% interest in its Saudi joint venture operation, taking its total holding to 60%, pending regulatory approvals. The address also contains an update on first-quarter trading and the year ahead, and notes the departure of a long-serving director from the Board.

Related sector context

Engineering, contracting and essential-services companies are influenced by government and private infrastructure spending, resources and energy capital programs, labour availability and project execution. On 22 October 2026, the S&P/ASX 200 Industrials [XNJ] index was at 8,199.50, up 1.05%, and the S&P/ASX 200 was at 8,788.70, up 0.48%. Their results are typically reported through revenue, margin, work in hand and new contract awards, and contract timing can move between reporting periods.

Work-in-hand and order book figures are widely used in the segment because they show contracted activity that has not yet been converted to revenue. Contract awards are announced to the market when they are material, and extensions or renewals can add to the period covered by existing agreements.

Risks to weigh in

Pharma revenue declined organically, and Coal and Oil & Lubricants experienced margin contraction despite revenue growth. The Saudi interest increase depends on regulatory approvals. Commodity cycles, laboratory capacity, labour costs, currency and regulatory changes can affect results, and the address is a speech rather than a full financial report.

Catalysts on watch

Items to watch include regulatory approval of the Saudi JV stake, progress on the Roadmap to Win and Lab of the Future, Pharma and Nuvisan results, and ALS’s first-half FY27 result.

Closing perspective

ALS’s 28 July 2026 AGM address summarised record safety and financial results, divisional growth and a larger Saudi stake. Subsequent results will provide formal figures for the period ahead.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.